# Clinical and Translational Study of MK-0646 in Patients With Metastatic Neuroendocrine Tumors (NET)

> **NCT00610129** · PHASE2 · COMPLETED · sponsor: **Memorial Sloan Kettering Cancer Center** · enrollment: 25 (actual)

## Conditions studied

- Neuroendocrine Tumors
- Metastatic Neuroendocrine Tumors

## Interventions

- **DRUG:** MK-0646

## Key facts

- **NCT ID:** NCT00610129
- **Lead sponsor:** Memorial Sloan Kettering Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-01
- **Primary completion:** 2010-01
- **Final completion:** 2010-01
- **Target enrollment:** 25 (ACTUAL)
- **Last updated:** 2015-11-20

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00610129

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00610129, "Clinical and Translational Study of MK-0646 in Patients With Metastatic Neuroendocrine Tumors (NET)". Retrieved via AI Analytics 2026-06-12 from https://api.ai-analytics.org/clinical/NCT00610129. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*